Search

Your search keyword '"O’Lone, Raegan"' showing total 19 results
Start Over Author "O’Lone, Raegan" Publication Year Range Last 10 years
19 results on '"O’Lone, Raegan"'

2. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study

Author

Ahn, Eugene R., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Ali-Ahmad, Hussein M., additional, Chan, John, additional, Maitland, Michael L., additional, Patel, Sapna R., additional, Reese, Zachary, additional, Balmanoukian, Ani S., additional, Drescher, Charles W., additional, Li, Rui, additional, Tsimberidou, Apostolia M., additional, Leath, Charles A., additional, O'Lone, Raegan, additional, Grantham, Gina N., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2023
Full Text
View/download PDF

3. Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Behl, Deepti, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Farrington, Laura Catherine, additional, Crysler, Oxana V., additional, Dib, Elie G., additional, Duvivier, Herbert Leon, additional, Hall, Michael J., additional, Salmon, John Stuart, additional, Alese, Olatunji B., additional, Marr, Alissa S., additional, Ngirailemesang, Isa, additional, Polavaram, Latha, additional, Thota, Ramya, additional, Yang, Eddy Shih-Hsin, additional, O'Lone, Raegan, additional, Grantham, Gina N., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2023
Full Text
View/download PDF

4. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study

Author

Yang, Eddy S., primary, Halabi, Susan, additional, Rothe, Michael, additional, Garrett-Mayer, Elizabeth, additional, Mangat, Pam K., additional, Pisick, Evan, additional, Dib, Elie, additional, Burgess, Earle F., additional, Zakem, Michael, additional, Rohatgi, Nitin, additional, Bilen, Mehmet A., additional, O'Lone, Raegan, additional, Grantham, Gina N., additional, and Schilsky, Richard L., additional

Published
2023
Full Text
View/download PDF

5. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Klute, Kelsey A., primary, Rothe, Michael, additional, Garrett-Mayer, Elizabeth, additional, Mangat, Pam K., additional, Nazemzadeh, Reza, additional, Yost, Kathleen J., additional, Duvivier, Herbert L., additional, Ahn, Eugene R., additional, Cannon, Timothy L., additional, Alese, Olatunji B., additional, Krauss, John C., additional, Thota, Ramya, additional, Calfa, Carmen J., additional, Denlinger, Crystal S., additional, O'Lone, Raegan, additional, Halabi, Susan, additional, Grantham, Gina N., additional, and Schilsky, Richard L., additional

Published
2022
Full Text
View/download PDF

6. Importance of investigating epigenetic alterations for industry and regulators: An appraisal of current efforts by the Health and Environmental Sciences Institute

Author

Miousse, Isabelle R., Currie, Richard, Datta, Kaushik, Ellinger-Ziegelbauer, Heidrun, French, John E., Harrill, Alison H., Koturbash, Igor, Lawton, Michael, Mann, Derek, Meehan, Richard R., Moggs, Jonathan G., O’Lone, Raegan, Rasoulpour, Reza J., Pera, Renee A. Reijo, and Thompson, Karol

Published
2015
Full Text
View/download PDF

8. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study

Author

Gupta, Ranju, primary, Meric-Bernstam, Funda, additional, Rothe, Michael, additional, Garrett-Mayer, Elizabeth, additional, Mangat, Pam K., additional, D'Andre, Stacy, additional, Ahn, Eugene R., additional, O'Lone, Raegan, additional, Halabi, Susan, additional, Grantham, Gina N., additional, and Schilsky, Richard L., additional

Published
2022
Full Text
View/download PDF

9. Abstract CT110: Olaparib (O) in patients (pts) with solid tumors with ATM mutation or deletion: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Mileham, Kathryn F., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Yang, Eddy S., additional, Alese, Olatunji B., additional, Jain, Angela, additional, Duvivier, Herbert L., additional, Palmbos, Phillip, additional, Ahn, Eugene R., additional, Aragon-Ching, Jeanny B., additional, Beekman, Kathleen W., additional, Behl, Deepti, additional, Meric-Bernstam, Funda, additional, Gutierrez, Rodolfo, additional, Sanford, Amy, additional, Thota, Ramya, additional, Zakem, Michael, additional, Zhao, Song, additional, O'Lone, Raegan, additional, Grantham, Gina N., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2022
Full Text
View/download PDF

10. Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Author

Srkalovic, Gordan, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Nazemzadeh, Reza, additional, Cannon, Timothy Lewis, additional, Duvivier, Herbert Leon, additional, Yost, Kathleen J, additional, Pakkala, Suchita, additional, Alva, Ajjai Shivaram, additional, Behl, Deepti, additional, Gold, Philip Jordan, additional, Calfa, Carmen Julia, additional, Ngirailemesang, Melissa, additional, Powell, Steven Francis, additional, O'Lone, Raegan, additional, Grantham, Gina N., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2022
Full Text
View/download PDF

11. Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study.

Author

Meric-Bernstam, Funda, primary, Rothe, Michael, additional, Garrett-Mayer, Elizabeth, additional, Gutierrez, Rodolfo, additional, Ahn, Eugene R, additional, Cannon, Timothy Lewis, additional, Powell, Steven Francis, additional, Krauss, John C., additional, Reynolds, Christopher M., additional, von Mehren, Margaret, additional, Behl, Deepti, additional, Calfa, Carmen Julia, additional, Duvivier, Herbert Leon, additional, Kaplan, Henry G., additional, Livingston, Michael B., additional, Sharma, Manish, additional, Urba, Walter John, additional, O'Lone, Raegan, additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2022
Full Text
View/download PDF

12. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1 / 2 Mutation: Results From the TAPUR Study.

Author

Yang, Eddy S., Halabi, Susan, Rothe, Michael, Garrett-Mayer, Elizabeth, Mangat, Pam K., Pisick, Evan, Dib, Elie, Burgess, Earle F., Zakem, Michael, Rohatgi, Nitin, Bilen, Mehmet A., O'Lone, Raegan, Grantham, Gina N., and Schilsky, Richard L.

Subjects
PROSTATE cancer patients, PROSTATE cancer, BRCA genes, OLAPARIB, CANCER patients, PROGRESSION-free survival
Abstract

PURPOSE: The TAPUR Study is a phase II basket trial that aims to evaluate activity of approved targeted agents in patients with advanced cancers with potentially actionable genomic variants. Data from a cohort of patients with metastatic castrate-resistant prostate cancer (mCRPC) and BRCA1 / 2 mutations treated with olaparib are reported. METHODS: Eligible patients with measurable mCRPC were matched to treatment according to protocol-specified genomic matching rules. Patients had no remaining standard treatment options, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function. Simon's two-stage design was used with a primary end point of disease control, defined as objective response or stable disease of at least 16-week duration. Secondary end points include radiographic progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS: Thirty patients with mCRPC with BRCA1 / 2 mutations were treated with olaparib. The disease control rate was 69% (95% CI, 51 to 81), and the objective response rate was 58% (95% CI, 37 to 77). The median radiographic progression-free survival and the median overall survival were 38.4 (95% CI, 16.3 to 52.1) weeks and 76.4 (95% CI, 49.3 to 106.0) weeks, respectively. Six of 30 (20%) patients experienced grade 3-4 adverse or serious adverse events including anemia, aspiration, decreased WBC count, and fatigue. CONCLUSION: Olaparib has antitumor activity in patients with mCRPC with BRCA1 / 2 mutations and warrants further study to determine how to best integrate it into the standard treatment of patients with BRCA1 / 2 -mutated prostate cancer. Olaparib showed a positive signal of activity in real-world patients w/prostate cancer w/BRCA1 or BRCA2 mutations @ASCO #TAPUR. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Two approaches for estimating the lower limit of quantitation (LLOQ) of microRNA levels assayed as exploratory biomarkers by RT-qPCR

Author

Wolfinger, Russell D., primary, Beedanagari, Sudheer, additional, Boitier, Eric, additional, Chen, Tao, additional, Couttet, Philippe, additional, Ellinger-Ziegelbauer, Heidrun, additional, Guillemain, Gregory, additional, Mariet, Claire, additional, Mouritzen, Peter, additional, O’Lone, Raegan, additional, Pine, P. Scott, additional, Sharapova, Tatiana, additional, Yan, Jian, additional, Yuen, Peter S., additional, and Thompson, Karol L., additional

Published
2018
Full Text
View/download PDF

16. Absolute Measurement of Cardiac Injury-Induced microRNAs in Biofluids across Multiple Test Sites

Author

Thompson, Karol L., primary, Boitier, Eric, additional, Chen, Tao, additional, Couttet, Philippe, additional, Ellinger-Ziegelbauer, Heidrun, additional, Goetschy, Manuela, additional, Guillemain, Gregory, additional, Kanki, Masayuki, additional, Kelsall, Janet, additional, Mariet, Claire, additional, de La Moureyre–Spire, Catherine, additional, Mouritzen, Peter, additional, Nassirpour, Rounak, additional, O’Lone, Raegan, additional, Pine, P. Scott, additional, Rosenzweig, Barry A., additional, Sharapova, Tatiana, additional, Smith, Aaron, additional, Uchiyama, Hidefumi, additional, Yan, Jian, additional, Yuen, Peter S., additional, and Wolfinger, Russ, additional

Published
2016
Full Text
View/download PDF

17. Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions

Author

Grimaldi, Christine, primary, Finco, Deborah, additional, Fort, Madeline M., additional, Gliddon, Daniel, additional, Harper, Kirsty, additional, Helms, Whitney S., additional, Mitchell, Jane A., additional, O’Lone, Raegan, additional, Parish, Stanley T., additional, Piche, Marie-Soleil, additional, Reed, Daniel M., additional, Reichmann, Gabriele, additional, Ryan, Patricia C., additional, Stebbings, Richard, additional, and Walker, Mindi, additional

Published
2016
Full Text
View/download PDF

18. Demodifying RNA for Transcriptomic Analyses of Archival Formalin-Fixed Paraffin-Embedded Samples.

Author

Wehmas, Leah C, Wood, Charles E, Gagne, Remi, Williams, Andrew, Yauk, Carole, Gosink, Mark M, Dalmas, Deidre, Hao, Ruixin, O'Lone, Raegan, and Hester, Susan

Subjects
FORMALDEHYDE, PARAFFIN wax, RNA sequencing, ORGANOCATALYSIS, CROSSLINKED polymers
Abstract

Archival formalin-fixed paraffin-embedded (FFPE) tissue samples offer a vast but largely untapped resource for genomic research. The primary technical issues limiting use of FFPE samples are RNA yield and quality. In this study, we evaluated methods to demodify RNA highly fragmented and crosslinked by formalin fixation. Primary endpoints were RNA recovery, RNA-sequencing quality metrics, and transcriptional responses to a reference chemical (phenobarbital, PB). Frozen mouse liver samples from control and PB groups (n = 6/group) were divided and preserved for 3 months as follows: frozen (FR); 70% ethanol (OH); 10% buffered formalin for 18 h followed by ethanol (18F); or 10% buffered formalin (3F). Samples from OH, 18F, and 3F groups were processed to FFPE blocks and sectioned for RNA isolation. Additional sections from 3F received the following demodification protocols to mitigate RNA damage: short heated incubation with Tris-Acetate-EDTA buffer; overnight heated incubation with an organocatalyst using 2 different isolation kits; or overnight heated incubation without organocatalyst. Ribo-depleted, stranded, total RNA libraries were built and sequenced using the Illumina HiSeq 2500 platform. Overnight incubation (± organocatalyst) increased RNA yield >3-fold and RNA integrity numbers and fragment analysis values by>1.5- and >3.0-fold, respectively, versus 3F. Postsequencing metrics also showed reduced bias in gene coverage and deletion rates for overnight incubation groups. All demodification groups had increased overlap for differentially expressed genes (77%-84%) and enriched pathways (91%-97%) with FR, with the highest overlap in the organocatalyst groups. These results demonstrate simple changes in RNA isolation methods that can enhance genomic analyses of FFPE samples. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

19. Development and validation of a high-throughput transcriptomic biomarker to address 21st century genetic toxicology needs.

Author

Heng-Hong Li, Hyduke, Daniel R., Fornace, Albert J., Renxiang Chen, Williams, Andrew, Yauk, Carole L., Frötschle, Roland, Ellinger-Ziegelbauer, Heidrun, O'Lone, Raegan, and Aubrecht, Jiri

Subjects
GENETIC toxicology, GENETIC transcription, BIOMARKERS, CANCER treatment, DNA damage
Abstract

Interpretation of positive genotoxicity findings using the current in vitro testing battery is a major challenge to industry and regulatory agencies. These tests, especially mammalian cell assays, have high sensitivity but suffer from low specificity, leading to high rates of irrelevant positive findings (i.e., positive results in vitro that are not relevant to human cancer hazard). We developed an in vitro transcriptomic biomarker-based approach that provides biological relevance to positive genotoxicity assay data, particularly for in vitro chromosome damage assays and propose its application for assessing the relevance of the in vitro positive results to carcinogenic hazard. The transcriptomic biomarker TGx-DDI (previously known as TGx-28.65) readily distinguishes DNA damage-inducing (DDI) agents from non-DDI agents. In this study, we demonstrated the ability of the biomarker to classify 45 test agents across a broad set of chemical classes as DDI or non-DDI. Furthermore, we assessed the biomarker's utility in derisking known irrelevant positive agents and evaluated its performance across analytical platforms. We correctly classified 90% (9 of 10) of chemicals with irrelevant positive findings in in vitro chromosome damage assays as negative. We developed a standardized experimental and analytical protocol for our transcriptomics biomarker, as well as an enhanced application of TGx-DDI for high-throughput cell-based genotoxicity testing using nCounter technology. This biomarker can be integrated in genetic hazard assessment as a follow-up to positive chromosome damage findings. In addition, we propose how it might be used in chemical screening and assessment. This approach offers an opportunity to significantly improve risk assessment and reduce cost. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results